[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhang Han\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100646411","phase-2-exosome-therapy-for-male-androgenetic-alopecia-100646411",false,"NCT07693244","Exosome Therapy for Male Androgenetic Alopecia","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Male Androgenetic Alopecia","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for enrollment:\n\n1. Male subjects aged 18 to 55 years;\n2. Diagnosis of androgenetic alopecia classified as Norwood-Hamilton grade III-V;\n3. Stable pattern of hair loss for at least 6 months prior to screening;\n4. Willingness to refrain from using any other hair loss treatments during the study period and for 6 months after completion of treatment.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Other types of alopecia, including alopecia areata, cicatricial alopecia, or telogen effluvium;\n2. Use of minoxidil, finasteride, spironolactone, or other hair growth-related medications within 1 year prior to screening;\n3. Receipt of platelet-rich plasma (PRP), laser cap therapy, or other scalp procedures within 6 months prior to screening;\n4. History of autoimmune disease, active scalp infection, coagulation disorders, or malignancy;\n5. Known hypersensitivity to the investigational product or any of its components;\n6. Inability to comply with study procedures, incomplete clinical data, or conditions that may interfere with efficacy evaluation;\n7. Participation in another clinical trial within the study period;\n8. Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.","MALE","18 Years","55 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if local scalp injection of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) can treat androgenetic alopecia (AGA) in male patients with AGA.\n\nThe main question it aims to answer is:\n\nDoes hUCMSC-Exos injection improve hair regrowth compared with placebo?\n\nResearchers will compare hUCMSC-Exos injection to placebo injection to see if hUCMSC-Exos leads to superior efficacy in hair follicle regeneration, as measured by changes in hair density, hair thickness, and patient-reported outcomes.\n\nParticipants will:\n\nReceive randomized, double-blinded local scalp injections of either hUCMSC-Exos or placebo\n\nAttend scheduled follow-up visits for hair assessment and safety monitoring\n\nUndergo photography, trichoscopy, and complete quality-of-life or psychosocial burden questionnaires as applicable",[27],"Androgenetic Alopecia (AGA)",[29,30,31,32,33],"Androgenetic Alopecia","Exosomes","hUCMSC-Exos","Mesenchymal Stem Cells","Randomized Controlled Trial","RECRUITING","2026-07-06",{"date":37,"type":38},"2026-07-09","ACTUAL",{"date":40,"type":38},"2026-04-30",{"date":42,"type":21},"2026-11-10",{"name":44,"class":45},"Zhang Han","OTHER",""]